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Abstract
Dengue virus (DENV) is a serious mosquito-borne pathogen causing significant global disease burden, either as classic
dengue fever (DF) or in its most severe manifestation dengue hemorrhagic fever (DHF). Nearly half of the world’s population
is at risk of dengue disease and there are estimated to be millions of infections annually; a situation which will continue to
worsen with increasing expansion of the mosquito vectors and epidemic DF/DHF. Currently there are no available licensed
vaccines or antivirals for dengue, although significant effort has been directed toward the development of safe and
efficacious dengue vaccines for over 30 years. Promising vaccine candidates are in development and testing phases, but a
better understanding of immune responses to DENV infection and vaccination is needed. Humoral immune responses to
DENV infection are complex and may exacerbate pathogenicity, yet are essential for immune protection. In this report, we
develop DENV-2 envelope (E) protein epitope-specific antigens and measure immunoglobulin responses to three distinct
epitopes in DENV-2 infected human serum samples. Immunoglobulin responses to DENV-2 infection exhibited significant
levels of individual variation. Antibody populations targeting broadly cross-reactive epitopes centered on the fusion peptide
in structural domain II were large, highly variable, and greater in primary than in secondary DENV-2 infected sera. E protein
domain III cross-reactive immunoglobulin populations were similarly variable and much larger in IgM than in IgG. DENV-2
specific domain III IgG formed a very small proportion of the antibody response yet was significantly correlated with DENV-2
neutralization, suggesting that the highly protective IgG recognizing this epitope in murine studies plays a role in humans
as well. This report begins to tease apart complex humoral immune responses to DENV infection and is thus important for
improving our understanding of dengue disease and immunological correlates of protection, relevant to DENV vaccine
development and testing.
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Introduction
Denguevirus(DENV)isthequintessential21
stcenturyre-emerging
infectious disease. Advances in post exposure treatment, epidemio-
logical understanding, and vector control did much to reduce dengue
disease burden in the past. However, in the last three decades DENV
has spread epidemically; dramatically increasing in disease severity
and range with overlapping co-circulation of the four DENV
serotypes spreading into geographic regions containing other
pathogenic flaviviruses [1,2,3]. Approximately 40% of the world’s
population, over 2.5 billion people, live at risk of infection in DENV-
endemic areas resulting in estimated millions of infections annually
[4,5]. Significant effort and resources have been applied toward
DENV vaccine development over the last 30 years, yet in spite of
promising vaccine candidates in development and/or early-phase
trials,asafeandefficaciousvaccineappearstostillbeyearsaway[5,6].
DENV consist of four closely related viral serotypes (DENV-1, -
2, -3, and -4) and as with the other flaviviruses, infection with any
single virus appears to provide life-long immunity with cross-
protection to other DENV serotypes being limited and transient
[7,8,9,10]. Human infections with DENV range from asymptom-
atic to an acute self-limiting febrile illness known as dengue fever
(DF) or with increasing frequency, a life-threatening hemorrhagic
fever and circulatory shock known as dengue hemorrhagic fever/
dengue shock syndrome (DHF/DSS) [2]. The DENV genome is a
positive-sense single-stranded RNA molecule, approximately
11 kb in length. It is transcribed as a single polyprotein encoding
three structural proteins; capsid (C), premembrane/membrane
(prM/M) and envelope (E) proteins and seven non-structural
proteins [11]. Mature virions contain an ER derived lipid bilayer
covered with a dense lattice of membrane-bound prM/M and E
proteins, organized into dimmers on its surface [12]. The E
protein is the primary protective antigen containing a highly
conserved internal fusion peptide and the cellular receptor-binding
motifs, both essential for viral infectivity via receptor-mediated
endocytosis [11,12,13,14]. DENV and all other flavivirus E
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[15,16,17]. The epitope specificity and biological characteristics
of antibody responses to the E protein are almost entirely deduced
from murine MAb studies. E protein domain I (ED1) is the central
domain and contains both virus-specific and cross-reactive,
predominately non-neutralizing epitopes; EDII, the dimerization
domain, contains the internal fusion peptide which forms the
epicenter of a series of overlapping immunodominant cross-
reactive epitopes stimulating predominately non- or weakly
neutralizing antibodies; EDIII has an immunoglobulin-like fold,
contains the primary cellular receptor-binding motifs and in mice
elicits virus-specific, highly protective neutralizing antibodies and
DENV complex cross-reactive antibodies [18,19,20,21,22,23,24,
25] (Fig. 1).
Infection with any DENV serotype thus produces a wide
spectrum of anti-E immunoglobulins varying from broadly cross-
reactive - recognizing all flaviviruses, to those recognizing only
subsets of viruses in different serocomplexes, those recognizing only
DENV-complex viruses to DENV serotype-specific antibodies. The
broadly cross-reactive antibodies stimulated from the overlapping
immunodominant epitopes surrounding the EDII fusion peptide are
predominantly non-neutralizing as evidenced by the general lack of
cross-protection between the flaviviruses [7,8,9,10,19,26]. DENV
complex and sub-complex cross-reactive antibodies stimulated from
overlapping epitopes in EDIII vary in their neutralizing capabilities
[18,22,24] and these antibodies can be protective as evidenced by
occasionally documented transient cross-protection between DENV
serotypes [9]. Secondary infection with a heterologous DENV
serotype stimulates a broadly cross-reactive anamnestic immune
response, which although not efficiently cross-protective, can cause
serious public health issues. The presence of cross-reactive anti-E
immunoglobulins in recovered human sera can create difficulty for
serodiagnosis and especially for estimates of disease burden in
regions with multiple co-circulating pathogenic flaviviruses. In
clinical serodiagnosis detecting IgM, this cross-reactivity is most
problematic with secondary infections due to the difficulty of
differentiating antibodies elicited by primary infections from those
elicited in a secondary infection [27,28,29]. For example, in Puerto
Ricosince1997allfourDENVserotypeswereco-circulatingandthe
vast majority of patient sera were secondary DENV infections. With
the arrival of West-Nile virus (WNV) into the Caribbean and
apparent DENV infections with neurological manifestations, clinical
serodiagnosis has become especially complicated (CDC Dengue
Branch pers. com., [30,31]). Serosurvey estimates of flavivirus
disease burden are even more problematic due to cross-reactive IgG
responses accumulated over a lifetime of multiple virus or
vaccination exposures.
The presence of cross-reactive anti-E immunoglobulins may
enhance the pathogenicity of flavivirus infections via the process of
antibody-dependent enhancement (ADE) of infection [32].
Although ADE has been demonstrated in vitro for encephalitic
as well as hemorrhagic flaviviruses [33] it is of greatest in vivo
concern with DENV infections where the severe pathogenic
manifestations DHF/DSS are correlated with secondary infections
and sub-neutralizing levels of heterologous anti-E immunoglobu-
lins [34,35,36]. Concern over ADE and its role in DHF/DSS has
instilled a belief in the necessity for tetravalent DENV vaccines
stimulating balanced immune responses across DENV serotypes to
reduce this concern [6,37,38]. However, multivalent DENV
candidate vaccine trials have been severely hampered by
difficulties in inducing a balanced serotype-specific immune
responses in vaccinees [37].
An important research agenda necessary to successfully address
the DENV global public health challenge is to improve our
understanding of humoral immune responses to DENV infection;
specifically the E-protein epitope-targeting of the immunoglobulin
response and the relative quantities of epitope-specific antibody
populations after viral exposure and vaccination in humans, the
infection neutralizing and/or enhancing capabilities of these
immunoglobulin populations and their role as correlates of
protection in vaccine efficacy studies [4,22,34,39,40,41,42]. As
an initial step toward this goal, in this report we develop a series of
E-protein epitope-specific knock-out virus-like particles (VLPs) and
use these antigens to measure humoral immune responses in
DENV-2 infected human sera from Puerto Rico and Taiwan. We
quantify immunoglobulin populations targeting four distinct E-
protein antigenic regions: the most broadly cross-reactive EDII
fusion peptide epitopes, EDIII serocomplex cross-reactive epi-
topes, epitopes incorporating determinates from either or both of
these domain regions, and EDIII DENV-2 type-specific epitopes.
Humoral immune responses in DENV-2 infected patient sera were
highly variable between individual sera and immunoglobulin class.
Immunoglobulin populations recognizing dominant cross reactive
epitopes centered on the EDII fusion peptide were large and
highly variable, averaging approximately 50% and 30% in
primary and secondary DENV-2 infected sera respectively.
Immunoglobulin recognizing DENV complex cross-reactive
epitopes in EDIII exhibited similar trends but the magnitudes
were smaller overall and the EDIII cross-reactive IgM response
was much greater than IgG in both primary and secondary
DENV-2 infected sera. Immunoglobulin populations recognizing
EDIII DENV-2 specific epitopes were very small though again
larger in IgM than in IgG. IgG recognizing this epitope averaged
only 1% of the immunoglobulin response yet the magnitudes of
EDIII virus-specific IgG were significantly correlated with DENV-
2 specific neutralization regardless of primary or secondary
infection status. The results presented in this report extend our
understanding of the diverse nature of humoral immune responses
to human DENV infection and we discuss their relevance in the
context of understanding DENV disease and the development of
safe and efficacious DENV vaccine candidates.
Results
Monoclonal Antibody Epitope Mapping
We examined the effects of substitutions in two distinct
antigenic regions of the E-glycoprotein, EDII and EDIII on
MAb reactivities (Fig. 1). The highly conserved fusion peptide
located in EDII is an immunodominant region containing multiple
overlapping epitopes typically eliciting weakly neutralizing and
widely cross-reactive antibodies against viruses from several major
serocomplexes [19,20,43,44,45]. DENV EDIII elicits predomi-
nately complex and sub-complex cross-reactive and virus-specific
antibodies, some of which can be potently neutralizing [18,22,24].
Previous studies of flavivirus epitope mapping have demonstrated
that different substitutions of an E-protein residue can have
distinct effects on both MAb reactivities and VLP secretion, and
that a specific substitution’s effect on MAb binding can vary
between flaviviruses [14,19,43,44,46]. For this reason we chose
first to determine the effect of individual E-protein substitutions on
MAb reactivity and VLP secretion, and then to combine
substitutions in an attempt to maximize both MAb reactivity
reductions and VLP secretion.
In the fusion peptide of EDII we examined two, five and six
different substitutions at Gly104, Gly106 and Leu107 respectively
(Fig. 1 and Table 1). As previously observed with different
substitutions and with other viruses, G104 substitutions dramat-
ically reduced VLP secretion from transiently transformed COS-1
DENV E-Protein Immune Response
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L107 residues reduced the reactivities predominately against
group-cross-reactive MAbs which recognize all flavivirus E
proteins (Tables 1 and 2, some data not shown). Based upon
these observations we combined three different substitutions at
G106 with two at L107 to create six double-mutant constructs. As
expected, the observed effects of the single substitutions on MAb
reactivities and VLP secretion typically combined additively into
Figure 1. Structural locations of envelope (E) protein epitope-specific knock-out substitutions. (A) Crystal structure of the DENV-2 E
protein dimer [15] as it appears from above in mature virions and depicted as a ribbon diagram. The structural domains are colored red (EDI), yellow
(EDII), and blue (EDIII). The highly conserved fusion peptide, located at the distal end of EDII is colored green and the glycans in EDI (N153) and EDII
(N67) are depicted as ball and stick representation and colored brown. Epitope specific knock-out substitutions in the fusion peptide and in EDIII are
depicted as space filling representations. (B) Side view of the same representation of the E protein dimer in mature virions with all structural
depictions and colors the same as in panel A. (C) An enlarged view from panel B of the interface between the EDII fusion peptide of one E monomer
and EDIII of the alternate monomer of the E dimer. EDII fusion peptide (EDIIFP), EDIII cross-reactive (EDIIICR), and EDIII DENV-2 serotype specific (EDIIITS)
antigenic regions are noted and encircled. Residues locations of epitope-specific knock out substitutions utilized in this study are depicted as ball and
stick representations. Substitutions of Gly106 and Leu107 in the EDII fusion peptide knock out the binding of broadly cross-reactive
immunoglobulins, those recognizing viruses in the DENV complex and other flavivirus complexes. Substitutions of Lys310, Glu311, Pro364, and
Lys388 in EDIII knock out the binding of immunoglobulins recognizing all or subsets of the four serotypes of DENV, but do not interfere with DENV-2
specific immunoglobulin recognition. Substitutions of Lys305 knock out the binding of DENV-2 serotype specific MAbs.
doi:10.1371/journal.pone.0004991.g001
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reactive MAbs, we also observed reactivity reductions for DENV
complex and subcomplex reactive MAbs D3-5C9-1, 9D12,
10A4D-2, and 1B4C-2 (Tables 1 and 2, some data not shown).
In general, reactivity reductions to these MAbs were less
pronounced than those observed with the more broadly cross-
reactive MAbs. Thus, combinations of substitutions acting as
epitope determinates in the EDII fusion peptide have a greater
effect than do individual substitutions on disrupting the binding of
some antibodies in this region. In DENV-2, fusion peptide residues
act as epitope determinates for antibodies with diverse patterns of
cross reactivity; predominately flavivirus group cross-reactive
antibodies, but also for MAbs recognizing only individual viruses
from different flavivirus serocomplexes, to DENV complex cross-
reactive MAbs. This appears to be a general phenomenon, as
recent reports in other flaviviruses demonstrate that antibodies
exhibiting varying levels of cross-reactivity recognize epitopes
including highly conserved fusion peptide residues
[19,25,43,44,46].
We next examined the effects of 15 amino acid substitutions at
eight different residues in EDIII, first alone and then in
combination (Table 1). The EDIII substitutions examined
primarily altered the reactivity of DENV complex MAbs
(Table 2). The residues that had the greatest effects on MAb
Table 1. Nucleotide sequences of mutagenic primers used and % VLP secretion from resultant plasmids relative to wild-type
(100%).
Primer Primer Sequence (59-39)
1
Nucleotide
Substitution
Amino Acid
Substitution % VLP Secretion
2
G104E TTTCCAAATAGTCCACATTCATTTCCCCATCCTCTGTCTACC GGA-GAA Gly-Glu ,0
G104H CCCTTTCCAAAT6AGTCCACAGTGATTTCCCCATCCTCTGTCTACC GGA-CAC Gly-His ,0
G106M GCCTCCCTTTCCAAATAGCATACATCCATTTCCCCATCC GGA-ATG Gly-Met 100
G106R GCCTCCCTTTCCAAATAGACGACATCCATTTCCCCATCC GGA-CGT Gly-Arg 100
G106D GCCTCCCTTTCCAAATAGATCACATCCATTTCCCCATCC GGA-GAT Gly-Asp 150
G106W GCCTCCCTTTCCAAATAGCCAACATCCATTTCCCCATCC GGA-TGG Gly-Trp ,50
G106Q GCCTCCCTTTCCAAATAGTTGACATCCATTTCCCCA GGA-CAA Gly-Gln 150
L107Q GCCTCCCTTTCCAAATTCTCCACATCCATTTCCCCATCC CTA-GAA Leu-Gln 150
L107D GCCTCCCTTTCCAAAATCTCCACATCCATTTCCCCATCC CTA-GAT Leu-Asp ,50
L107M GCCTCCCTTTCCAAACATTCCACATCCATTTCCCCATCC CTA-ATG Leu-Met 50
L107G GCCTCCCTTTCCAAAACCTCCACATCCATTTCCCCATCC CTA-GGT Leu-Gly 100
L107K GGTCACAATGCCTCCCTTTCCAAATTTTCCACATCCATTTCCCC CTA-AAA Leu-Lys 75
L107F GCCTCCCTTTCCAAAAAATCCACATCCATTTCCCCATCC CTA-TTT Leu-Phe 150
G106D/L107K CACAATGCCTCCCTTTCCAAATTTGTCACATCCATTTCCCCATCC GGA-GAC CTA-AAA Gly-Asp Leu-Lys 67
G106D/L107D CACAATGCCTCCCTTTCCAAAGTCGTCACATCCATTTCCCCATCC GGA-GAC CTA-GAC Gly-Asp Leu-Asp ,5
G106R/L107D CACAATGCCTCCCTTTCCAAAGTCGCGACATCCATTTCCCCATCC GGA-CGC CTA-GAC Gly-Arg Leu-Asp 8
G106R/L107K CACAATGCCTCCCTTTCCAAACTTGCGACATCCATTTCCCCATCC GGA-CGC CTA-AAG Gly-Arg Leu-Lys 85
G106W/L107K CACAATGCCTCCCTTTCCAAACTTCCAACATCCATTTCCCCATCC GGA-TGG CTA-AAG Gly-Trp Leu-Lys 17
G106W/L107D CACAATGCCTCCCTTTCCAAAGTCCCAACATCCATTTCCCCATCC GGA-TGG CTA-GAC Gly-Trp Leu-Asp 67
K305E TATTTCCTTCACAACTTTAAACTCTCCTGTGCACATAGAG AAG-GAG Lys-Glu 6
K305N TATTTCCTTCACAACTTTAAAGTTTCCTGTGCACATAGAG AAG-AAC Lys-Asn 13
V308N CCATGTTGTGTTTCTGCTATTTCCTTCACATTTTTAAACTTTCCTGT GTT-AAT Val-Asn 19
K310E TGTGTTTCTGCTATTTCCTCCACAACTTTAAACTTTCCTGT AAG-GAG Lys-Glu 25
K310Q TGTGTTTCTGCTATTTCCTGCACAACTTTAAACTTTCCTGT AAG-CAG Lys-Gln 38
E311R CCATGTTGTGTTTCTGCTATTCGCTTCACAACTTTAAACTTTCCTG GAA-CGA Glu-Arg 100
E311K CCATGTTGTGTTTCTGCTATTTTCTTCACAACTTTAAACTTTCCTG GAA-AAA Glu-Lys 38
E311Y CCATGTTGTGTTTCTGCTATGTACTTCACAACTTTAAACTTTCCTG GAA-TAC Glu-Tyr 6
K310E/E311R GTGTTTCTGCTATTCGCTCCACAACTTTAAACTTTCCTGTGC AAG-GAG GAA-GGA Lys-Glu Glu-Arg 25
R323E CCGTCCCCTTCATATTGCACTTCGATAACTATTGTTCCAT AGA-GAA Arg-Glu 6
R323M CCGTCCCCTTCATATTGCACCATGATAACTATTGTTCCAT AGA-ATG Arg-Met 17
K361D TATGTTGACTGGGCTATCATCTTCTGTCACAATTGGGTTG AAA-GAT Lys-Asp 38
P364R AGGTTCTGCTTCTATGTTGACCCGGCTATCTTTTTCTGTC CCA-CGG Pro-Arg 25
P364E GGAGGTTCTGCTTCTATGTTGACTTCGCTATCTTTTTCTGTC CCA-GGA Pro-Glu 25
K388D GCTTCCTTTCTTAAACCAGTTGAGATCCAGTTGTCCCG AAG-GAT Lys-Asp 50
K388E GCTTCCTTTCTTAAACCAGTTGAGTTCCAGTTGTCCCG AAG-GAA Lys-Glu 50
1Mutated nucleotides are shown in bold.
2Average of triplicate experiments of mutant VLP secretion from transiently transformed COS-1 cells, standardized against the wild-type DENV-2 plasmid VLP secretion.
doi:10.1371/journal.pone.0004991.t001
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Table 2). The MAbs affected by substitutions at these four residues
exhibited three different reactivity patterns: those recognizing
some but not all viruses in both the JEV and DENV
serocomplexes (MAbs 20 and 5-1), MAbs recognizing only viruses
within the DENV complex (1A1D-2, 9D12, 10A4D-2, and 1B4C-
2) and DENV-2 type-specific MAbs (3H5). The K305 substitutions
(K305E and K305N) were the only EDIII substitutions that
significantly affected DENV-2 type-specific antibody recognition.
K305 substitutions also affected DENV complex MAb 1A1D-2.
There were no significant effects of the K305 substitutions for
other DENV complex MAbs.
Some of the same antibodies exhibiting reactivity reductions
from fusion peptide substitutions were also affected by EDIII
substitutions (Table 2). For example, MAb 5-1 exhibited reactivity
reductions to all six fusion peptide double mutant VLPs and also
for one of three E311 substitutions. VLPs containing the charge
reversal substitution E311R lost all measurable ELISA recognition
by MAb 5-1 yet VLPs containing the alternative charge reversal
substitution E311K or E311Y were unchanged. Similarly, DENV
subcomplex MAb 10A4D-2 exhibited reactivity reductions for
VLPs containing substitutions in either EDIII or the EDII fusion
peptide. These results extend previous observations that some
cross-reactive antibodies might recognize intra-E dimer epitopes
spatially overlapping EDII and EDIII structural domains of
independent monomers [44,45].
The third class of antibodies recognizing epitope determinates
in EDIII were DENV complex and subcomplex MAbs. The
antibody panel contained six DENV complex cross-reactive
MAbs, three raised from DENV-2 and one each from the other
three serotypes. The two MAbs exhibiting the greatest decreases in
EDIII reactivity were 1A1D-2 and 9D12, subcomplex reactive
MAbs raised against DENV-2 and -1 respectively (Table 2).
1A1D-2 reactivity was reduced by single substitutions at all DIII
residues investigated with the exception of K361, consistent with
recent crystal structure data from the 1A1D-2 antigen-binding
fragment complexed with recombinant DENV-2 EDIII (Tables 1
and 2;[47]). MAb 9D12 reactivity was only affected by the K310
and P364 individual substitutions. However, EDIII substitutions,
both individual and in combination did not dramatically affect the
reactivity of DENV complex reactive MAbs 1B7 or D3-5C9-1,
antibodies raised against DENV-3 and -4 respectively (Table 2).
Substitutions from the EDII fusion peptide and from EDIII
were combined into the same plasmid construct in an attempt to
maximize reductions in cross-reactive antibody recognition of
epitopes incorporating these two disparate structural regions. The
general effect on MAb reactivities of combining substitutions was
predictably additive. In general there was little effect of DIII
substitutions on the group cross-reactive MAbs, and limited effect
of fusion peptide substitutions on most complex and subcomplex
MAbs. When substitutions were combined together the resulting
VLPs exhibited reduced reactivities to both classes of antibodies
(Table 2). We also observed significant reductions in the reactivity
of DENV-4 derived complex cross-reactive MAb D3-5C9-1. By
combining epitope determinates from both domains we were able
to construct mutant VLPs exhibiting significantly reduced or
ablated reactivity to the majority of MAbs in the panel
representing five distinct reactivity classes: group, subgroup,
complex and subcomplex cross-reactive, and DENV-2 specific
antibodies (Table 2). Thus, this series of cross-reactive and DENV-
2 specific epitope knock-out VLPs can be utilized as serodiagnostic
antigens to characterize the epitope-specific targeting of the
polyclonal human immunoglobulin response to DENV infection.
Epitope-specific Humoral Immune Responses of DENV-2
Infected Patients
We selected a number of well-characterized DENV-2 infected
patient sera to examine the epitope-specific proportions of the
Figure 2. Envelope protein structural domain III (EDIII) alignment of representative strains of the four dengue virus (DENV)
serotypes and Japanese encephalitis virus (JEV). Single letter amino acid abbreviations are shown for EDIII of DENV-2 using DENV-2 numbering
(the last digit of the residue number lies directly above the numbered residue). Amino acids conserved relative to DENV-2 in the other serotypes are
shown as dots, alignment gaps are depicted with dashes, and single letter abbreviations for non-conserved amino acids are shown. Colored residues
in the DENV-2 sequence depict epitope-specific determinates as determined in this report and previously published reports. DENV complex and
subcomplex cross-reactive epitopes are highlighted in yellow, DENV-2 specific residues are highlighted in red, and residues from the region of
overlap between these epitopes (hence affecting DENV complex and DENV-2 virus specific epitopes) are highlighted green [22,23,24,47]. The
substituted EDIII residues incorporated into mutant antigens in this study are marked in black for the non DENV-2 viruses: DENV EDIII complex cross-
reactive knock out mutants incorporated K310D, E311R, P364R, and K388D; K305E was utilized to determine EDIII DENV-2 specific immunoglobulin
responses.
doi:10.1371/journal.pone.0004991.g002
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VLP antigens described in this report. All serum specimens were
collected 6–18 days post onset of symptoms (dpo) from DENV-2
infected individuals suffering from dengue fever and were viral
RNA positive as determined by a DENV-2 specific reverse
transcriptase-PCR (RT-PCR) assay (Table 3). Primary and
secondary DENV-2 infected patient sera were selected from each
of two different geographic regions; Puerto Rico and Taiwan
(Table 3). IgM and IgG end-point titers were determined using six
distinct DENV-2 VLP antigens to estimate the proportions of
immunoglobulin recognizing four distinct E-protein antigenic
regions (Table 2). Wild-type (WT) DENV-2 VLP was used to
determine total anti-E IgM and IgG titers. Immunoglobulin
proportions targeting EDII fusion peptide epitopes were deter-
mined with EDII fusion peptide knock-out mutant G106R-L107D
(EDIIFP). Immunoglobulin recognizing cross-reactive epitopes in
EDIII was determined with the EDIII cross-reactive knock-out
mutant K310E-E311R-P364R (EDIIICR) and total immunoglob-
ulin proportions recognizing all cross-reactive epitopes incorpo-
rating determinates in either or both EDII fusion peptide and/or
EDIII were determined with an EDII-III combination of these two
knock-out mutants G106R-L107D-K310E-E311R-P364R (EDIIF-
P2EDIIICR). The proportion of EDIII DENV-2 virus-specific
immunoglobulin was determined as the difference between the
EDIII K305E and K388D antigen reactivities (EDIIITS; Fig. 1c, 2,
and Table 2). Endpoint titers of each serum specimen were
determined concurrently in IgM and IgG antibody-capture ELISA
with each DENV-2 antigen and a negative antigen. As described
in the methods section, immunoglobulin endpoints were calculated
for the different VLP antigens using asymptotic covariance matrix
V method by regression analysis with four variables: antigen class,
immunoglobulin class (IgM, IgG), primary or secondary infection
status, and the resident country of infected patients (Puerto Rico or
Taiwan); and a general least squares (GLS) approach was applied
to determine endpoints. Because the mutant antigens are epitope
knock-outs, the domain-associated, epitope specific immunoglob-
ulin percentages were determined by dividing the endpoint titer
determined with a knock-out antigen by the titer of the WT
antigen, subtracting this value from 1.0 and multiplying by 100.
DENV-2 virus specific imunoglobulin percentages were deter-
mined as the difference between the percent recognizing the
K305E and the K388D antigens.
Results from ANOVA on the GLS regression indicated that the
three-way interaction among antigen, immunoglobulin type and
geographic origin was not statistically significant (p=0.6810). This
result suggests that the patterns observed in mean endpoints
among the different antigens, within the same immunoglobulin
class are similar for sera collected from two different geographic
locations, Taiwan or Puerto Rico. Because this three-way
interaction was not significant we reran the ANOVA examining
only main and two-way interactions (Table 4). There is evidence
that the two-way interactions between immunoglobulin type and
primary or secondary infection status (p,0.0001), between antigen
class and primary or secondary infection status (p,0.0001),
between antigen class and geographic origin (p=0.0403), and
between antigen class and immunoglobulin type (p,0.0001) were
statistically significant. There were highly significant effects of
three of the four individual variables on epitope-specific endpoint
titers (p,0.0001); the only individual variable not having a
significant effect on antigen endpoints was the geographic origin of
the sera (p=0.0709). In other words, there were no differences in
total endpoint titer averaged across the different antigens, between
the DENV-2 infected patient sera from Puerto Rico and from
Taiwan (Table 4). The significant interaction between antigen
class and geography does however indicate that there could be
significant geographical effects on the magnitudes of individual
epitope-specific immunoglobulin populations. Such differences
could arise either from differential immune status correlated with
geography and/or from the different genetic backgrounds of
patients from Taiwan and Puerto Rico.
Because the ANOVA results suggest no generalized effect of
geographic origin of test sera, the source of sera are not further
specified unless indicated. Endpoint titers of E-protein specific
immunoglobulins from DENV-2 infected patient sera (measured
with the WT DENV-2 antigen) ranged from 21,400–1,510,000
(mean=299,000) for IgM and from 12,400–11,000,000 for IgG
(mean=2,400,000; Table 5). Primary DENV-2 infected patient
sera exhibited similar IgM and IgG titers for individuals and as a
class these sera had IgM and IgG titers ranging from 21,400–
1,510,000 (mean=408,000) and 12,400–1,020,000 (mean=
376,000) respectively (Table 6). Secondary DENV-2 infected
patient sera exhibited a distinctly different pattern with IgG titers
Table 3. Serological characterization of DENV-2 infected sera
examined in this study.
Sera #
Country of
Origin DPO
1 1u/2u
2 IgM P/N IgG P/N
M/G
OD-N
3
4 Taiwan 17 1u 46.0 20.4 1.65
5 Taiwan 17 1u 27.8 10.3 2.53
12 Taiwan 14 1u 33.7 29.0 1.19
16 Taiwan 18 1u 5.02 3.59 1.25
8882 Puerto Rico 6 1u 44.2 5.04 11.1
0078 Puerto Rico 10 1u 65.0 12.1 4.23
9 Taiwan 14 2u 35.6 24.4 0.91
10 Taiwan 18 2u 15.6 24.1 0.41
17 Taiwan 14 2u 6.1 24 0.21
0169 Puerto Rico 6 2u 29.2 35.4 0.65
9608 Puerto Rico 13 2u 33.4 39.8 0.78
8867 Puerto Rico 7 2u 53.6 54.2 1.04
1DPO denotes days post onset of symptoms.
2denotes primary (1u) or secondary (2u) DENV-2 infection.
3This column denotes the ratio of the optical density (OD) for IgM/divided by
IgG. Each value is corrected by subtracting 2 times the negative OD value.
doi:10.1371/journal.pone.0004991.t003
Table 4. Analysis of variance table of calculated DENV-2
infected serum end-point data determined with different
epitope specific antigens.
Variable F-value p-value
Antigen 370 ,0.0001
Immunoglobulin type 239 ,0.0001
1u or 2u Infection 362 ,0.0001
Geographic origin of Sera 3.36 0.0709
Antigen : Immunoglobulin type 17.7 ,0.0001
Antigen : Geographic origin of Sera 2.91 0.0403
Antigen : 1u or 2u Infection 30.8 ,0.0001
Immunoglobulin type : 1u or 2u Infection 118 ,0.0001
doi:10.1371/journal.pone.0004991.t004
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within individual sera (21,900–447,000; mean=189,000 for IgM
and 2,290,000–11,000,000; mean=4,430,000 for IgG; Table 6).
The larger magnitude IgG response in secondary DENV
infections could result from the rapid and strong memory B-
and T-cell response and the increased frequency of reduced IgM
response in secondary DENV infections [28]. Although all serum
specimens were late acute to early convalescent phase (6–18 dpo)
this is sufficient time for typically rapid and strong anamnestic IgG
responses.
Cross-reactive immunoglobulin populations from two
overlapping antigenic regions form the majority of the
immune response and are greater in magnitude for IgM
than for IgG
Immunoglobulin proportions targeting cross-reactive EDII
fusion peptide epitopes were highly variable yet tended to be
large, and were distinctly greater in primary than in secondary
DENV-2 infected patients. EDII fusion peptide specific immuno-
globulin responses ranged from undetectable levels to 97% of IgM
and from undetectable to 94% of IgG; the mean and median
values were 44% and 34% of IgM and 36% and 36% of IgG
respectively (Table 5). The larger magnitude fusion peptide-
specific immunoglobulin response in primary versus secondary
DENV-2 infections was greater in IgM than in IgG (54% vs. 24%
and 44% vs. 35% in IgM and IgG respectively; Table 6). EDII
fusion peptide-specific IgM comprised a greater percentage of the
total IgM response for the DENV-2 infected patient sera from
Taiwan (51%) than it did for the Puerto Rican sera (33%). This
was the only epitope-specific immunoglobulin subclass where there
was a dramatic percent difference between serum specimens from
the two geographic regions. The significance of these differences is
supported by the ANOVA results: although there was non-
significant trend towards an effect of geographic origin of the sera
alone on the total immunoglobulin titers (p=0.0709) there was a
significant two-way interaction between epitope-specific antigen
classes and the geographic origin of the sera on these end-points
(p=0.0403; Table 4).
Immunoglobulin targeting cross-reactive EDIII epitopes showed
similar trends as did that recognizing EDII fusion peptide epitopes
but their variability and magnitudes were smaller and there was an
even greater reduction in IgG titers relative to IgM. EDIII cross-
reactive immunoglobulin ranged from ,1% to 45% in primary
infections and ,1% to 90% in secondary infections. IgM
recognizing cross-reactive EDIII epitopes averaged 37% and
55% in primary and secondary infections respectively, whereas
EDIII cross-reactive IgG averaged only 7.5% and 4% of primary
and secondary DENV-2 infected patient sera (Table 6). Thus,
there was a much greater EDIII cross-reactive IgM response than
in IgG and for IgM this response was greater in secondary than in
primary infections.
In addition to the EDII fusion peptide and the EDIII cross-
reactive epitope knock-out antigens, serum specimens were
screened with an EDII2EDIII knock-out antigen, combining
the same substitutions from the individual mutant antigens in these
two antigenic regions (EDIIFP2EDIIICR; Table 2). Immunoglob-
ulin recognizing epitopes in either of -or overlapping- these
structural domain regions averaged 58% of IgM and 72% of the
Table 5. Epitope Specific Proportions of Envelope Protein Specific IgM and IgG from DENV-2 Infected Human Sera.
DENV-2 Antigen
1
Epitope Specific
Target
2
Mean Endpoint
Titer
3
Endpoint Titer
Range
Range of Percent
Response
4
Mean (Median) Percent
Epitope Specific Response
IgM
WT All 2.99610
5 2.14610
4–1.51610
6 100 100
G106R-L107D*{ EDIIFP 1.66610
5 6.07610
2–4.79610
5 ,1–97 44 (34)
K310E-E311R-P364R{ EDIIICR 1.71610
5 1.59610
4–8.32610
5 ,1–90 43 (39)
G106R-L107D-K310E-E311R-
P364R*
EDIIFP2EDIIICR 1.26610
5 5.00610
2–3.98610
5 ,1–91 58 (67)
K305E-K388D EDIIITS 1.79610
4 2.19610
2–7.98610
4 ,1–20 6 (4.5)
IgG
WT*{ All 2.40610
6 1.24610
4–1.10610
7 100 100
G106R-L107D* EDIIFP 1.54610
6 7.37610
2–4.79610
6 ,1–94 36 (36)
K310E-E311R-P364R{ EDIIICR 2.46610
6 1.16610
4–1.05610
7 ,1–26 5.8 (13)
G106R-L107D-K310E-E311R-
P364R
EDIIFP2EDIIICR 6.76610
5 4.74610
2–1.70610
6 ,1–96 72 (64)
K305E-K388D EDIIITS 2.40610
4 1.24610
2–4.50610
5 ,1–8 1 (,1)
1The mutant antigens used are all knock-out mutants. The symbols * and { depict significantly different mean endpoint titers determined with antigens sharing the
same symbol. Mean endpoint titers were considered significantly different when the 95% confidence interval for the difference between the means did not cross zero.
2Epitope specific antibody populations targeted by the different knock-out antigens. WT antigen measures antibody recognizing all E-protein epitopes. EDIIFP denotes
broadly cross-reactive epitopes incorporating the E-protein structural domain II fusion peptide. EDIIICR denotes predominately complex cross-reactive epitopes
incorporating residues within E-protein structural domain III. EDIIFP2EDIIICR denotes individual or overlapping epitopes incorporating either or both the EDII fusion
peptide or EDIII. EDIIITS denotes EDIII DENV-2 type-specific epitopes and were determined by the reactivity difference between the K305E and K388D antigens (see
methods for details).
3Endpoint titers determined with the knock-out antigen, thus representing immunoglobulins recognizing epitopes not targeted by the knock-out antigen. Because the
EDIII DENV-2 type-specific response was calculated as the percent difference between K305E and K388D reactivities, the titers for EDIIITS were calculated as the WT
titers multiplied by the percent EDIIITS response.
4Because the mutant antigens knock-out antibody recognition of specific epitopes, the percent of immunoglobulin recognizing a particular epitope was determined for
each individual sera by calculating the percent reactivity measured with a mutant antigen relative to that determined with the WT antigen and subtracting this value
from 1.0; (1- [Endpointmutant/Endpointwt])6100; for the percent DENV-2 specific reactivity we used (1-[(EndpointK305E/EndpointWT)2(EndpointK388D)/EndpointWT)])6100.
doi:10.1371/journal.pone.0004991.t005
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was a greater total cross-reactive IgM response in primary versus
secondary DENV-2 infected sera (63% and 48% respectively).
However, this pattern was reversed in IgG where 55% and 73%
recognized these cross-reactive epitopes in primary and secondary
DENV-2 infected sera respectively (Table 6). Interestingly, the
percent cross-reactive immunoglobulin as determined with the
EDIIFP2EDIIICR antigen was not the same as estimated by the
adding the percents of immunoglobulin recognizing the EDII
fusion peptide and cross-reactive EDIII epitopes (Tables 5 and 6).
There were exceptions to this general observation for IgM or IgG
for some individual serum specimens. The total proportion of
cross-reactive immunoglobulin determined with the EDIIFP2E-
DIIICR antigen was greater than that estimated by adding the
percentages determined with the EDIIFP and EDIIICR antigens for
IgG (72% and 42% respectively), yet the opposite pattern was
observed for IgM (EDIIFP2EDIIICR=58%; EDIIFP+E-
DIIICR=87%; Table 5). These data suggest that there are
different patterns of E-protein antigenicity between IgM and IgG.
In the MAb screening we observed significant reactivity reductions
with DENV complex cross-reactive MAb D3-5C9-1 for the inter-
domain EDIIFP2EDIIICR antigen, yet no reactivity reductions of
this MAb for either the EDIIFP or the EDIIICR antigens alone
(Table 2). Thus, a proportion of human IgG might recognize
epitopes similar to murine MAb D3-5C9-1 or they might
recognize epitopes not represented in our MAb panel that
similarly exhibit reduced recognition for the EDIIFP2EDIIICR
antigen and not for either the EDIIFP or EDIIICR antigens alone.
Immunoglobulin populations targeting EDIII DENV-2
specific epitopes are small yet of greater magnitude in
IgM than in IgG and in secondary than in primary DENV-2
infected sera
To determine the proportion of immunoglobulin recognizing
EDIII DENV-2 type-specific epitopes identified as potently
neutralizing in murine studies we used two different EDIII mutant
Table 6. Epitope Specific Proportions of Envelope Protein Specific IgM and IgG from Primary and Secondary DENV-2 Infected
Human Sera.
Infection
Status DENV-2 Antigen
1
Epitope Specific
Target
2
Mean End-point
Titer
3
Endpoint Titer
Range
Mean Percent Epitope
Specific Response
4
IgM
Primary WT All 4.08610
5 2.14610
4–1.51610
6 100
G106R-L107D EDIIFP 1.89610
5 6.07610
2–4.79610
5 54
K310E-E311R-P364R EDIIICR 2.57610
5 1.59610
4–8.32610
5 37
G106R-L107D-K310E-E311R-P364R EDIIFP2EDIIICR 1.53610
5 5.00610
2–3.47610
5 63
K305E-K388D EDIIITS 1.70610
4 1.07610
3–2.74610
4 4
Secondary WT*{ All 1.89610
5 2.19610
4–4.47610
5 100
G106R-L107D* EDIIFP 1.44610
5 1.66610
4–4.07610
5 24
K310E-E311R-P364R EDIIICR 8.55610
4 1.95610
4–2.34610
5 55
G106R-L107D-K310E-E311R-P364R{ EDIIFP2EDIIICR 9.91610
4 1.32610
4–3.98610
5 48
K305E-K388D EDIIITS 1.48610
4 2.19610
2–3.66610
4 8
IgG
Primary WT All 3.76610
5 1.24610
4–1.02610
6 100
G106R-L107D EDIIFP 2.10610
5 7.37610
2–6.92610
5 44
K310E-E311R-P364R EDIIICR 3.60610
5 1.16610
4–8.91610
5 7.5
G106R-L107D-K310E-E311R-P364R EDIIFP2EDIIICR 1.68610
5 4.74610
2–4.90610
5 55
K305E-K388D EDIIITS 3.76610
3 1.24610
2–1.02610
4 ,1
Secondary WT*{ All 4.43610
6 2.29610
6–1.10610
7 100
G106R-L107D*{ EDIIFP 2.87610
6 1.45610
6–4.79610
6 35
K310E-E311R-P364R EDIIICR 4.57610
6 2.00610
6–1.05610
7 4.0
G106R-L107D-K310E-E311R-P364R EDIIFP2EDIIICR 1.18610
6 7.08610
5–1.70610
6 73
K305E-K388D EDIIITS 8.86610
4 2.29610
4–4.50610
5 2
1The mutant antigens used are all knock-out mutants. The symbols * and { depict significantly different mean endpoint titers between those antigens sharing the same
symbol. Mean endpoint titers were considered significantly different when the 95% CI for the difference between the mean endpoints did not cross zero.
2Epitope specific antibody populations targeted by the different knock-out antigens. WT antigen measures antibody recognizing all E-protein epitopes. EDIIFP denotes
broadly cross-reactive epitopes incorporating the E-protein structural domain II fusion peptide. EDIIICR denotes predominately complex cross-reactive epitopes
incorporating residues within E-protein structural domain III. EDIIFP2EDIIICR denotes individual or overlapping epitopes incorporating either or both the EDII fusion
peptide or EDIII. EDIIITS denotes EDIII DENV-2 type-specific epitopes and were determined by the reactivity difference between the K305E and K388D antigens (see
methods for details).
3Endpoint titer determined with the knock-out antigen, thus representing immunoglobulins recognizing epitopes not targeted by the knock-out antigen. Because the
EDIII DENV-2 type-specific response was calculated as the percent difference between K305E and K388D reactivities, the titers for EDIIITS were calculated as the WT
titers multiplied by the percent EDIIITS response.
4Because the mutant antigens knock-out antibody recognition of specific epitopes, the percent of immunoglobulin recognizing a particular epitope was determined for
each individual sera by calculating the percent reactivity measured with a mutant antigen relative to that determined with the WT antigen and subtracting this value
from 1.0; (1- [Endpointmutant/Endpointwt])6100; for the percent DENV-2 specific reactivity we used (1-[(EndpointK305E/EndpointWT)2(EndpointK388D)/EndpointWT)])6100.
doi:10.1371/journal.pone.0004991.t006
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the prototype DENV-2 type-specific MAb recognizing this
epitope. K305 has been demonstrated to be essential for the
binding of MAb 3H5 and six other potently neutralizing DENV-2
specific MAbs [23]. However, K305E also reduced the reactivity
of subcomplex cross-reactive neutralizing MAb 1A1D-2 (Table 2).
The K388D antigen reduced only the reactivity of MAb 1A1D-2 -
to similar levels as did K305E and both of these residues have been
identified as 1A1D-2 binding residues in a recent DENV-2
structural determination with this MAb [47]. The amount of
EDIII DENV-2 specific immunoglobulin was therefore deter-
mined as the difference in the percent reduction in endpoint titer
relative to WT, between the K305E and K388D antigens.
EDIII DENV-2 virus-specific immunoglobulin formed very
small percentages of the antibody response and was greater in IgM
than in IgG. In contrast to the cross-reactive immunoglobulins
however, EDIII virus-specific antibody populations averaged twice
as large in secondary as in primary DENV-2 infected patient sera
(Tables 5 and 6). EDIII DENV-2 specific IgM averaged 6%, was
4% and 8% in primary and secondary DENV-2 infections, and
ranged from ,1% to 20%. EDIII DENV-2 specific IgG averaged
only 1% across all sera tested, was ,1% and 2% in primary and
secondary serum samples, and ranged from ,1% to 8% of total
IgG. Interestingly, serum specimens with the highest percent
EDIII DENV-2 specific IgM response were not the same as those
with the highest percent IgG targeting this epitope.
Neutralizing antibody responses of primary and
secondary DENV-2 infected patient sera: EDIII DENV-2
specific IgG titer is correlated with DENV-2 neutralization
Focus-reduction micro-neutralization (FRmNT) assays were
conducted with the sera to see if homologous/heterologous virus
neutralization correlated with differential percentages or titers of
virus-specific or cross-reactive immunoglobulin populations. All
sera were tested against five different viruses, DENV-1, -2, -3, -4,
and JEV; the Puerto Rican sera were additionally screened against
WNV. Serum samples were diluted two-fold from 1:50 until the
last positive dilution representing the 90% FRmNT titer was
reached. Actual 90% endpoint titers were also calculated by a non-
linear regression of the FRmNT data using a variable slope
sigmoidal dose-response formula. The 90% neutralization titers of
primary DENV-2 infected patient sera ranged from 1:200 to 1:800
and all were greater than or equal to four-fold higher than the next
highest virus titer (Table 7). Secondary DENV-2 infected patient
sera had much higher DENV-2 90% neutralization titers ranging
from 1:400 to 1:6400 (calculated 90% range: 431 to 11,174,
Table 8). Only two of the secondary DENV-infected sera had
DENV-2 neutralization titers four-fold or greater than of other
DENV serotypes (sera #0169 and #8867). Puerto Rico #9608
and Taiwan #9 each had equal 90% neutralization titers to
another serotype, DENV-4 and DENV-1 respectively. Taiwan
serum specimens #10 and #17 each had 90% neutralization titers
four-fold and two-fold higher respectively for DENV-1 than for
the currently infecting DENV-2, (Table 8). The period of
neutralizing antibody dominance to the primary infecting virus
after secondary infection with a heterologous DENV serotype has
been shown to vary from less than a week to multiple weeks, so
presumably these four serum specimens, collected 13–18 dpo have
therefore not switched or are in the process of switching to DENV-
2 dominance [28]. Most patient sera had JEV 90% neutralization
titers ,50, however, secondary DENV-2 infected serum samples
#9 and #10 had calculated JEV 90% neutralization titers of 83
and 103 respectively. This was not surprising for these two
Taiwanese sera since they were also IgG ELISA positive against
JEV VLP antigen [25]. We were surprised that the three
secondary DENV-2 infected patient sera from Puerto Rico
exhibited positive 90% neutralization titers against JEV, greater
than expected from DENV infected cross-reactivity. Because the
Puerto Rico sera were collected in 2007 when WNV was known to
be circulating on the island we decided post hoc to test all of the
Puerto Rico sera for neutralizing antibodies against WNV. The
three secondary DENV-2 infected specimens had calculated 90%
neutralization titers against WNV of 122, 74, and 59. The primary
DENV-2 specimens from Puerto Rico had calculated 90%
neutralization titers of ,15 for both JEV and WNV. Three
primary DENV-2 infected sera from Taiwan had calculated JEV
90% neutralization titers ,8 and one was 18 (Table 8). Taken
together these results suggest that there is limited cross-
Table 7. Virus neutralization titers for primary DENV-2
infected serum samples from dengue fever patients.
Serum #
Country of
Origin DPO
1 Virus
90% FRmNT
titer
2
Calculated 90%
FRmNT Titer
3
4 Taiwan 17 DENV-1 ,50 17
DENV-2 400 373
DENV-3 ,50 18
DENV-4 ,50 29
JEV ,50 7
5 Taiwan 17 DENV-1 ,50 3
DENV-2 800 706
DENV-3 ,50 10
DENV-4 ,50 16
JEV ,50 4
12 Taiwan 14 DENV-1 50 56
DENV-2 400 603
DENV-3 50 50
DENV-4 ,50 45
JEV ,50 18
16 Taiwan 18 DENV-1 ,50 4
DENV-2 400 411
DENV-3 ,50 7
DENV-4 ,50 13
JEV ,50 3
8882 Puerto Rico 6 DENV-1 ,50 9
DENV-2 200 144
DENV-3 ,50 15
DENV-4 ,50 24
WNV ,50 4
JEV ,50 3
0078 Puerto Rico 10 DENV-1 ,50 16
DENV-2 200 145
DENV-3 ,50 31
DENV-4 ,50 64
WNV ,50 12
JEV ,50 3
1days post onset of symptoms.
2Last positive titer in 90% Focus-reduction micro-neutralization (FRmNT) assay.
3Calculated actual 90% neutralization titers based on a nonlinear regression of
the FRmNT data using a variable slope sigmoidal dose-response model.
doi:10.1371/journal.pone.0004991.t007
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viruses in the JEV serocomplex. Thus, for at least one, and
possibly all three of the secondary DENV-2 infected sera from
Puerto Rico, the presence of JEV neutralizing antibody is
consistent with JEV complex-cross-reactivity occurring from
actual WNV exposure. We did not observe any significant
correlations between the proportions or the total magnitude of
cross-reactive immunoglobulin populations and heterologous
neutralization to other DENV serotypes or to JEV or WNV,
implying that the large cross-reactive antibody populations were
either weakly or non-neutralizing or that there was large variation
in the neutralizing capabilities of these immunoglobulins between
serum specimens.
To investigate if EDIII virus specific epitopes stimulate strongly
neutralizing and protective immunoglobulin in humans as they do in
mice we regressed EDIII DENV-2-specific (EDIIITS) IgM or IgG
titers (log10, y-axis) on the actual DENV-2 90% neutralization titers
(log 10) and performed an analysis of variance on the resulting
regression (Fig. 3). For IgM, the regression slope was actually
negative and not significantly different from 0 (m=20.163,
p=0.656), suggesting that IgM recognizing EDIIITS epitopes in
these sera is not strongly neutralizing. However, when EDIIITS IgG
titers were regressed on DENV-2 neutralization, the slope was
positive and significant (m=1.036, p=0.0149) indicating that
increasing EDIII DENV-2 specific IgG is correlated with increasing
neutralization (Fig. 3). These data suggest that the very small
proportion of EDIII DENV-2 specific IgG is responsible for a
significant proportion of DENV-2 specific neutralization, and that
the potently neutralizing EDIII virus-specific epitopes identified in
mice also play a role in DENV-2 specific neutralization in humans.
Discussion
MAb Epitope Mapping
Previous studies have indicated that the EDII fusion peptide
region contains multiple, overlapping, broadly cross-reactive,
Table 8. Virus neutralization titers for secondary DENV-2
infected serum samples from dengue fever patients.
Serum
#
Country of
Origin DPO
1 Virus
90% FRmNT
titer
2
Calculated 90%
FRmNT Titer
3
9 Taiwan 14 DENV-1 6400 7378
DENV-2 6400 11,174
DENV-3 800 2376
DENV-4 800 589
JEV ,50 83
10 Taiwan 18 DENV-1 25600 25,334
DENV-2 6400 6743
DENV-3 320 3024
DENV-4 800 991
JEV 50 103
17 Taiwan 14 DENV-1 6400 4179
DENV-2 3200 2076
DENV-3 3200 2898
DENV-4 800 915
JEV ,50 3
0169 Puerto Rico 6 DENV-1 200 306
DENV-2 3200 3821
DENV-3 800 934
DENV-4 200 167
WNV ,50 59
JEV ,50 17
9608 Puerto Rico 13 DENV-1 50 79
DENV-2 400 431
DENV-3 100 95
DENV-4 400 526
WNV ,50 74
JEV ,50 25
8867 Puerto Rico 7 DENV-1 200 366
DENV-2 3200 3177
DENV-3 100 135
DENV-4 800 1341
WNV 50 122
JEV ,50 38
1days post onset of symptoms.
2Last positive titer in 90% Focus-reduction micro-neutralization (FRmNT) assay.
3Calculated actual 90% neutralization titers based on a nonlinear regression of
the FRmNT data using a variable slope sigmoidal dose-response model.
doi:10.1371/journal.pone.0004991.t008
Figure 3. Envelope protein domain III DENV-2 specific (EDIIITS)
IgG is positively and significantly correlated with DENV-2
neutralization. Log10 EDIIITS IgM and IgG regressed on Log10 DENV-2
specific 90% neutralization endpoint titers. (A) EDIIITS IgM titer is not
associated with DENV-2 specific 90% neutralization titers (m=20.163,
p=0.656), P value was determined by performing an analysis of
variance on the slope of the regression. (B) EDIIITS IgG is positively and
significantly associated with increasing DENV-2 specific 90% Neutrali-
zation titers (m=1.036, p=0.0149), P value determined as in A.
doi:10.1371/journal.pone.0004991.g003
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DENV complex cross-reactive epitopes are located in EDIII
[18,19,20,21,22,23,24,25,43,44,45,46,48]. The mutagenesis-based
epitope mapping presented here supports and extends these
results. Substitutions at either G106 or L107 ablate most group
cross-reactive MAb recognition. This pattern was upheld in the
current study with the exception of L107F which did not
significantly reduce the binding of any group cross-reactive MAbs
(data not shown). However, in JEV, WNV, SLEV, and tick-borne
encephalitis virus (TBEV) E proteins the L107F substitution has
been shown to reduce cross-reactive antibody recognition, and
L107F TBEV recombinant subviral particles have been shown to
reduce immunoglobulin recognition in polyclonal DENV infected
human serum [14,19,43,44]. In spite of the invariant nature of
most fusion peptide residues, L107F does occur in a number of
flaviviruses: Powassan and Deer Tick viruses, JEV vaccine strain
SA-14-14-2, and DENV-2 strain POU-280 [49,50,51].
One of the more novel findings of the epitope mapping is that
substitutions in different structural domains of adjacent E-protein
monomers can act as epitope determinates for a single antibody
suggesting that some antibodies might recognize inter-monomer
epitopes including the disparate structural domains EDII and
EDIII. Perhaps the best example of this was DENV-4 derived
DENV complex cross-reactive MAb D3-5C9-1. This MAb
exhibited only minor reactivity reductions (50–25%) for all six
G106/L107 fusion peptide mutants and for two individual EDIII
mutants E311R and P364R (50%). However, when the EDII
fusion peptide and EDIII substitutions were combined into a single
VLP construct, D3-5C9-1 reactivity was reduced to only 1.5% of
WT DENV-2 reactivity. Such synergistic effects of combining
substitutions on antibody reactivity could occur when residues do
not play a critical binding role within the antibody paratope and
thus the introduction of single substitutions might not severely
interfere with antibody binding, yet when two or more
substitutions of little to no individual effect are combined together,
the combination either decreases Ka or increases Kd to the point
where a significant reduction in antibody recognition is observed.
Other examples of EDII2EDIII inter-monomer epitope determi-
nates occurred with DENV subcomplex MAb 1B4C-2 and
subgroup cross-reactive MAbs 5-1, and 5-2. MAb 1B4C-2 is a
DENV-2 derived non-neutralizing antibody recognizing a surface
accessible epitope originally assigned to EDI [18]. A previously
published mutagenesis study demonstrated that EDII fusion
peptide residues could act as epitope determinates affecting the
binding of this MAb [20], and this study confirms the effect of both
fusion peptide substitutions and EDIII substitutions acting as
1B4C-2 epitope determinates. Similar to MAb D3-5C9-1, the
greatest decreases in binding of 1B4C-2 occurred for VLPs
combining substitutions from both EDII and EDIII (Table 2).
MAb 5-1 is a JEV derived antibody that recognizes only JEV
and DENV-2. All VLPs containing G106/L107 substitutions
exhibited reduced binding by this MAb, as did E311R VLPs.
Again, combinations of the EDII substitutions with EDIII E311R
ablated all measurable MAb recognition for this VLP. MAb 20 is
similar to MAb 5-1; it was raised against DENV-2 and also
recognizes only JEV and DENV-2. Although fusion peptide
substitutions did not alter the binding of this MAb, just as with
MAb 5-1 all mutant VLPs containing combinations of E311
substitutions exhibited significant reductions in MAb 20 binding.
E311 is conserved across the DENV complex and is an asparagine
in the JEV complex viruses (Fig. 2); adjacent residue K310 is
almost completely conserved across the mosquito borne flavivi-
ruses, however K310 substitutions did not alter the binding of
either MAb 20 or 5-1. Thus other shared residues between
DENV-2 and JEV, possibly including fusion peptide residues,
must be responsible for the identical cross-reactivity patterns of
these two antibodies. MAb 5-2 is another JEV-derived subgroup
cross-reactive MAb, recognizing JEV, DENV-1 and DENV-2.
This study did not identify any substitutions in DENV-2 VLPs that
disrupted the binding of this MAb. However, in JEV and in
DENV-1, substitutions in both the fusion peptide and in EDIII
significantly reduce the binding of this MAb [25].
The only other published report of similar inter-monomer
EDII2EDIII epitopes is for chimpanzee MAb 1A5, a flavivirus
group cross-reactive MAb raised against mixed infection of all four
DENV serotypes [45]. G106 and H317 were independently
identified from neutralization escape variants of MAb 1A5 and
thus identified as epitope determinates. G106V significantly
reduced antibody binding and neutralization whereas H317Q
did not affect binding but did reduce neutralization by this MAb.
Although structurally close to G106 (,15A ˚) H317 lies buried on
the bottom membrane surface of the E dimer in native virions,
consistent with its lack of effect on 1A5 binding. The EDIII residue
we identified as cooperating with fusion peptide residues G106 and
L107 as a cross-reactive epitope determinate was E311. E311 is
highly exposed on the outer surface of the dimer and is only 6–9A ˚
from EDII fusion peptide residues G106 and L107 of the alternate
monomer, well within the binding area of a typical Fab footprint
(Fig. 1). Previously published competitive binding assays with
DENV-2 identified an overlapping epitope cluster including MAbs
recognizing fusion peptide epitopes such as 6B6C-1, EDIII
epitopes such as 1A1D-2 and also MAb 1B4C-2, identified as
recognizing an EDII2EDIII inter-domain epitope in this study
[18]. These observations suggest that such inter-domain epitopes
could be more common than previously recognized. It has been
noted in this report and elsewhere that there is a diversity of
overlapping epitopes containing fusion peptide residues recognized
by antibodies with variable patterns of cross-reactivity [43,44].
Due to the size of an antibody Fab footprint, it is expected that
such epitopes will include residues outside of, and less conserved
than those in the fusion peptide itself and that binding to these
variable residues must account for the different patterns of cross-
reactivity observed for antibodies recognizing epitopes in this
region. Thus, it is not unexpected that there are antibody epitopes
incorporating EDII fusion peptide residues and residues within the
structurally adjacent EDIII of the alternate monomer. These
results and interpretations suggest a point of caution for studies
attempting to map antibody epitopes using only recombinant
EDIII (rEDIII) protein or soluble E-protein monomers.
Some of the general and specific epitope mapping results
presented here are supported by recently published studies. A
number of studies have mapped DENV-complex and sub-complex
cross-reactive epitopes to the lateral surface of EDIII
[15,16,22,24,47,48]. MAb 1A1D-2 is a DENV-2 derived sub-
complex cross-reactive antibody that recognizes DENV-1, -2, and
-3 [18]. We identified six residues located on three different b-
strands in EDIII acting as epitope determinates for this antibody.
Four of these residues are in b-strand A (Lys305, Val308, Lys310,
and Glu311), and one each in b2strand B (Arg323) and b2strand
G (Lys388) [15]. The seventh residue identified as an epitope
determinate for this MAb, Pro364 is the last residue of the loop
just prior to b2strand E. Recently published analyses using yeast
surface display mutagenesis of DENV-2 rEDIII also identified
MAb 1A1D-2 epitope determinates in b2strand A (Gly304,
Lys305, Lys 307, and Lys310; [22]. In fact, a crystal structure of
MAb 1A1D-2 Fab complexed with rEDIII was recently solved and
confirms the principle involvement of EDIII b2strand A in 1A1D-
2 binding [47]. Another recent study examined five different
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as 1A1D-2. All five of these MAbs recognized a single antigenic
site including residues in b2strands A, B, and G and centered on
K310 [24]. It therefore appears that the well-characterized epitope
recognized by MAb 1A1D-2 could be representative of most
subcomplex antibodies recognizing DENV-1, -2, and -3.
MAb 9D12 was raised against DENV-1 and recognizes DENV-
1, -2, and -4. This MAb appears to recognize an overlapping, yet
distinct epitope from MAb 1A1D-2. Two of the residues we
identified as epitope determinates for 1A1D-2 had similar effects
on 9D12 reactivity; K310 and P364. Yeast display mutagenesis of
rEDIII also identified the involvement of K310, but they did not
examine the effect of substitutions at P364 for either 1A1D-2 or
9D12 binding [22]. There was one direct conflict between the
9D12 results presented here and those from a previous study. In
this report there was no effect of the substitutions examined at
K305 on 9D12 reactivity, whereas a previous study using rEDIII
found significant reductions in 9D12 binding for a K305E mutant
[22]. One possibility is that there could be subtle differences in
EDIII conformational structure between VLPs and rEDIII. For
example, there could be differences in local dynamic motions, and
hence minor conformational perturbations of the K305E substi-
tution when introduced into rEDIII compared to E protein dimers
as displayed on the VLP surface. Such local dynamic motions have
recently been observed in a recombinant EDIII system and
demonstrated to be associated with nearby substitutions that
correlate with reductions in MAb recognition and neutralization
[52]. DENV complex cross-reactive MAb 4E11, which we did not
examine, has been studied extensively in DENV-1 and also binds
to a discontinuous EDIII epitope centered primarily around four
residues in b2strand A, including K310 [48].
DENV type-specific antibodies, specifically the potently neu-
tralizing murine MAbs, recognize epitopes in DIII
[17,18,22,23,53,54,55,56]. Although we purposefully selected
amino acids that were likely to be incorporated into cross-reactive
epitopes for this study we identified one residue, K305 that
reduced the binding of the DENV-2-specific neutralizing MAb
3H5. 3H5 appears to be typical of many DENV-2 specific
neutralizing MAbs, recognizing similar overlapping epitopes
centered around EDIII residues K305 and P384 [22,23].
Interestingly, in the same rEDIII yeast surface display mutagenesis
study, P384 was identified as an important DENV-2 specific
epitope determinate, yet not K305; despite the use of MAb 3H5
and K305 mutants in both of the previous and in this current study
[22]. Sukupolvi-Petty et al. identified G304 as a major DENV-2
specific neutralizing MAb epitope determinate, G304 substitutions
were not examined in this study or by Gromowski and Barrett and
given its close proximity to K305, G304 could be included as a
part of this epitope [22,23]. A clear consensus result from all of
these studies is that there exist two different overlapping antigenic
regions on the lateral surface of EDIII, one stimulating antibody
with varying levels of cross-reactivity in the DENV serocomplex
and the other stimulatingDENV-2 virus-specific antibodies (Fig. 2).
These results all stem from studies of murine MAbs and a major
issue to be addressed is weather the outer lateral surface of DIII
contains protective virus-specific neutralizing epitope determinates
for humans as well [57].
Characterization of DENV-2 Infected Patient’s Serum
Recently there has been increased interest to examine and
dissect complex polyclonal human immune responses to flavivirus
infection. The results presented in this study compliment and add
to this nascent body of work with detailed epitope-specific
antibody assignments for IgM in addition to IgG. Stiasny et al.
measured total E-specific IgG titers from six DENV-2 infected
patient sera that ranged from 10
4 to 10
6 [19]; similar magnitudes
and variation as determined in this study. Another recent study of
WNV epitope-specific immune responses found much smaller and
less variable E-specific IgG titers in WNV-infected patient sera
(10
3–10
4) [26]. These WNV-infected sera were collected 4–7
months post onset of symptoms although a few sera collected less
than one month post onset had similar IgG titers. The DENV-2
infected sera examined by Stiasny et al had low to no IgM,
consistent with their also being convalescent phase sera. These
observations suggest that the different magnitudes of E-specific
IgG between DENV-2 and WNV infected patient sera in these
studies could be a virus specific phenomenon. DENV viremia in
humans lasts approximately 4–10 days whereas WNV viremia is
more transient, lasting only 1–3 days. Thus, the larger magnitude
IgG response in DENV-2 infected patients compared to WNV-
infected patients could result from differences in the length of
viremia between these two viruses. Clearly, more studies will be
needed to determine if this is a general phenomenon. In this study,
E-specific IgM titers for primary and secondary infected sera were
also in the 10
4–10
6 range (Table 5), although IgM titers were not
presented in the WNV study cited above, they would be expected
to be low based on the late convalescent timing of the serum
collections.
The importance of the EDII fusion peptide as an immunodo-
minant antigenic region containing a series of overlapping epitopes
stimulating broadly cross-reactive antibodies has been well-
established in mice [19,20,26,43,44]. The results presented in this
report and other recent studies confirm the extension of this
observation to humans as well [19,26,58]. In this study IgG
recognizing EDII fusion peptide epitopes ranged from undetect-
able to 94% of the E-specific IgG response and averaged 36%
(Table 5). Stiasny et al also found variable levels of EDII fusion
peptide recognizing IgG in DENV-2 infected patient sera, they did
not quantify this variation but estimated the proportion of IgG
recognizing these epitopes to average about 30% and confirmed
the limited neutralizing capability of this antibody population [19].
Because their study examined convalescent phase sera, the similar
percentage estimates of IgG targeting EDII fusion peptide epitopes
in these studies suggest that the high concentrations of these cross-
reactive antibodies are long-lived. This observation is also
supported by flavivirus serodiagnostic studies identifying high
levels of cross-reactivity in IgG assays [25,28,59]. Interestingly,
although 4–7 months is not particularly long, the continued
persistence of large populations of weakly or non-neutralizing
cross-reactive antibody is relevant to antibody-dependent en-
hancement of infection and its potential role in increasing DENV
disease severity leading to DHF/DSS [36,60,61]. Because
antibody stimulated from EDII fusion peptide epitopes tends to
be broadly cross-reactive, it is not surprising that the immunodo-
minant nature of EDII fusion peptide epitopes is also supported by
recent studies of WNV-infected human sera [26,62].
We examined both primary and secondary DENV-2 infected
patient sera and found EDII fusion peptide specific IgG was
greater in primary than in secondary infections (mean=44% and
35% respectively; Table 6). Lai et al recently used western blot to
examine late acute-early convalescent phase DENV-2 sera from
Taiwan [58]. They also found that the majority of the cross-
reactive antibody response targeted epitopes in the highly
conserved EDII fusion peptide. Moreover, Lai et al observed that
the EDII-fusion peptide specific antibody response was greater in
primary than in secondary DENV-2 infected patients, although
they assayed total immunoglobulin and did not distinguish
between IgM and IgG in their assays. The results presented in
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primary relative to secondary DENV-2 infected sera results more
from IgM than from IgG. IgM populations targeting these cross-
reactive epitopes in primary and secondary infections were larger
than IgG populations, and EDII fusion peptide specific IgM
averaged twice as large in primary infected sera (54% and 24% of
IgM in primary and secondary infections respectively, Table 6).
IgM responses to cross-reactive EDIII epitopes were similar in
variability and magnitude as were those for the EDII fusion
peptide, but the proportion of IgG recognizing these epitopes was
much smaller (Table 5 and 6). Flavivirus immune responses
targeting EDIII have not been examined in humans to the extent
that they have for EDII fusion peptide epitopes, and neither of the
DENV-2 infected patient sera studies cited above examined
immune responses to EDIII. Oliphant et al recently studied
epitope-specific immune responses in convalescent phase WNV-
infected patient sera, examining both total EDIII IgG and EDIII
WNV-specific IgG, the latter epitope being homologous to that
examined for DENV-2 in this report [26]. Total IgG recognizing
EDIII epitopes in the WNV sera averaged 7.3% and ranged from
0.6% to 50.5%, suggesting that the relatively small yet variable
magnitude cross-reactive EDIII IgG response we estimated from
DENV-2 infected patient sera (mean=5.8%, range ,1%–26%)
could be a generalized response to flavivirus infection. More
studies are needed to determine if the larger magnitude cross-
reactive IgM response relative to IgG and the greater cross-
reactive EDIII IgM in secondary relative to primary DENV-2
infections found in this study are typical for dengue or other
flaviviruses. If so, the use of IgM titers or P/Ns alone to attempt to
assign current infecting serotype in secondary DENV infections
could be highly misleading. This observation is supported by
detailed IgM and IgG analyses of a large number of primary and
secondary DENV infected serum specimens (Chang et al,
unpublished results).
Lai et al [58] examined late acute to early convalescent DENV-
2 infected human serum specimens from Taiwan, similar to the
Taiwanese serum specimens from this study. Using western blot to
assay total immunoglobulin they estimated the DENV-2 specific
anti E protein response in primary DENV-2 infections to range
from 0% to 8.6% with a single specimen estimated at 21.5%. They
did not attempt to identify the epitopes recognized by this DENV-
2 specific immunoglobulin. Our results in primary DENV-2
infected patient sera were similar (,1%–9%) and indicate that the
majority of this DENV-2 specific immunoglobulin is IgM
(mean=4% and ,1% for IgM and IgG). We found the same
pattern in secondary DENV-2 infected patients, but the
magnitude of IgM and IgG responses averaged twice as large as
in primary infections. The similar ranges of total DENV-2 specific
immunoglobulin identified by Lai et al and of EDIII virus-specific
IgM and IgG identified in the present study, suggest the possibility
that DENV-2 specific epitopes in EDIII might constitute and elicit
the majority of the virus-specific immune response in humans.
Oliphant et al also found small proportions of EDIII recognizing
virus specific IgG in WNV infected sera (mean=1.6%, range 0%–
6.8%), they did not however investigate WNV-specific epitopes
outside of EDIII [26].
We were able to demonstrate for the first time that there is a
significant and positive correlation between the magnitude of
EDIII DENV-2 specific IgG titer and the percent of DENV-2
specific neutralization in humans. In WNV however, there was no
correlation between overall levels of EDIII WNV-specific IgG and
clinical outcome or measurable difference in neutralization profiles
between WT and EDIII WNV-specific knock-out reporter virus
particles using a flow-cytometric assay, suggesting a limited role for
EDIII virus-specific IgG in WNV protective neutralization [26].
The apparent discrepancy between the importance of EDIII virus
specific IgG as a correlate of protection in DENV-2 and WNV in
these studies could result from the different neutralization assays
that were utilized. One possible biological explanation for this
discrepancy is the large titer differences between the two antibody
populations in these studies, despite averaging about 1% of the
IgG response against each virus. Total DENV-2 IgG titers, and
hence EDIII DENV-2 specific IgG ranged from 10–100-fold
greater than WNV IgG in the primary DENV-2 infected sera and
up to 1000-fold greater in the secondary DENV-2 infected patient
sera. A definitive test to see if these minor IgG populations are
indeed protective would be to examine DENV-2 or WNV re-
exposed vaccinee sera and determine if there is a marked
anamnestic increase in this antibody population that is associated
with increased protection. Nevertheless, our results suggest that the
EDIII virus-specific epitopes stimulating strongly neutralizing and
protective IgG in mice could play a similar role against DENV-2
infection in humans. The conclusions and questions stemming
from the results presented in this report begin to disentangle the
complex polyclonal humoral immune responses to primary and
secondary DENV infections and point a direction for future
studies in this field that will be essential both for improving our
understanding of DENV pathogenesis and for the development of
DENV vaccine candidates that may reduce the potential risk of
antibody-dependent enhancement in vaccinees.
Materials and Methods
Cell culture, construction of plasmids and virus-like
particle (VLP) production
COS-1 cells (ATCC CRL 1650; Manassas, VA) were grown at
37uC with 5% CO2 on Dulbeco’s modified Eagle’s minimal
essential medium (D-MEM, GIBCO, Grand Island, NY) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS,
Hyclone Laboratories, Inc., Logan, UT), 110 mg/l sodium
pyruvate, 0.1 mM nonessential amino acids, 2 mM L-glutamine,
20 ml/l 7.5% NaHCO3, 100 U/ml penicillin, and 100 ug/ml
streptomycin. We used the recombinant expression plasmid
pVAXD2i derived from pCBD2-2J-2-9-1 which been previously
characterized and described in detail [20,63]. This derivation is
the same as same as described for constructing pVJE from pCBJE
previously [25]. COS-1 cells were electroporated with WT
pVAXD2i and mutant plasmids using the protocol described in
[64]. Electroporated cells were recovered in 50 ml DMEM, seeded
into three separate 75 cm
2 culture flasks for VLP expression and
incubated at 28uC with 5% CO2. Tissue-culture medium was
harvested 4–5 days post transformation for VLP antigen
characterization including triplicate measurements of secretion
levels and MAb reactivity screening.
Selection and introduction cross-reactive epitope residue
substitutions
Cross-reactive epitope residues selected for substitution in the
fusion peptide eliciting cross-reactive antibodies were originally
identified by Crill and Chang, [20] with subsequent publications
emphasizing the importance of overlapping immunodominant
epitopes in this region [19,26,29,43,44,45,46]. Prospective EDIII
cross-reactive epitope residues were also selected based on
previously described procedural algorithms [20,44]. Using this
structure-based design approach we identified 22 different
probably EDIII cross-reactive epitope residues. We modeled the
effects of side-chain substitutions at eight of these residues using
the DENV-2 Protein Data Bank E-protein structural coordinates
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selecting those with the highest probability of disrupting antibody
binding without altering E-glycoprotein structural conformation,
particle formation, or secretion [15] (http://us.expasy.org/spdbv/).
Applying these criteria we selected 15 amino acid substitutions to
introduce at these eight EDIII residue positions (Table 1).
Site-specific mutations were introduced into the DENV-2 E
gene using the Stratagene Quick ChangeH multi site-directed
mutagenesis kit (Stratagene, La Jolla, CA) and pVAXD2i as DNA
template following the manufacturer’s recommended protocols.
The sequences of the mutagenic primers used for all constructs are
listed in Table 1. Structural gene regions and regulatory elements
of all plasmids were sequenced entirely upon identification of the
correct mutation. Automated DNA sequencing was performed
using a Beckman Coulter CEQ
TM 8000 genetic analysis system
(Beckman Coulter, Fullerton, CA) and analyzed using Beckman
Coulter CEQ
TM 8000 (Beckman Coulter) and LasergeneH
software (DNASTAR, Madison, WI).
Characterization of wild-type (WT) and mutant pVAXD2i
secreted VLP antigen
Antigen-capture ELISA (Ag-ELISA) was used to detect and
quantify secreted antigen from the mutagenized and WT
pVAXD2i transformed COS-1 cells. Secreted antigen was
captured in the inner 60 wells of Immulon II HB flat-bottom
96-well plates (Dynatech Industries, Inc., Chantilly, VA) with
polyclonal rabbit anti-DENV-2 WT VLP hyper-immune sera
diluted 1:500, incubated overnight at 4uC, and wells were blocked
with 300 ml of StartBlock blocking buffer (Pierce, Rockford, Ill.)
according to the manufacturer’s recommended protocol. Antigen
was diluted 2-fold in PBS, incubated for 2 hr at 37uC and detected
with murine hyper-immune ascitic fluid (MHIAF) specific for
DENV-2 diluted 1:2000 in 5% milk/PBS. Both the polyclonal
capture and detector sera are hyper-immune fluids produced
through repeated immunization and therefore containing high-
titer immunoglobulin recognizing all potential antigenic epitopes.
These polyclonal fluids are used at high concentration to insure
that all VLP antigens, even those with dramatically altered
epitopes, should be captured and detected similarly. MHIAF was
detected using horseradish peroxidase conjugated goat anti-mouse
IgG (Jackson ImmunoResearch, Westgrove, PA) in 5% milk/PBS
and incubated for 1 hr at 37uC. Bound conjugate was detected
with 3,395,59-tetramethylbenzidine substrate (TMB; Neogen
Corp., Lexington, KY), the reaction was stopped with 2N
H2SO4 and measured at A450 using a Synergy HT Multi-
Detection Microplate Reader (Bio-Tek Instruments, Inc., Wi-
nooski, VA). WT and mutant antigens were screened against the
MAb panel using the same ELISA protocol as above with the
exception that 2-fold dilutions of the specific MAb replaced the
anti-DENV-2 MHIAF and antigens were used at a single
standardized concentration producing an optical density (OD) of
1.0 in the secretion ELISA. Standardized concentrations of WT
and mutant VLP antigens were analyzed in Ag-ELISA to
determine MAb end point reactivities [18].
Monoclonal antibodies
MAbs 4G2, 6B6C-1, 4A1B-9, 1B7, D3-5C9-1, 1A1D-9, 9D12,
10A4D-2, 1B4C-2, 9A3D-8, and 3H5 were obtained from the
Arbovirus Diseases Branch, Division of Vector-borne Infectious
Diseases, US Centers for Disease Control and Prevention (CDC).
Many of these MAbs originated from the work of John Roehrig,
4G2, 1B7, 9D12, and 3H5 hybridomas were originally obtained
by the CDC from the Walter Reed Army Institute [65]. MAbs 23-
1, 23-2, 20, 5-1 and 5-2 were provided by Dr. L.-K. Chen, Tzu
Chi University, Hualien, Taiwan.
Human DENV-2 infected sera and basic serological
characterization
DENV-2 infected human sera from dengue fever patients were
obtained from the Dengue Branch, CDC, San Juan, Puerto Rico;
and also from the Taiwan Center for Disease Control. The Puerto
Rican DENV-infected patient sera were collected from Puerto
Ricans infected locally during the 2007 transmission season and
the Taiwanese sera were from Taiwanese residents who contracted
DENV-2 while traveling in SE Asia outside of Taiwan in 2005. All
sera were confirmed DENV-2 positive by virus isolation or RT-
PCR either from these specimens or from paired acute-phase sera
(data not presented and collected in either Puerto Rico or
Taiwan).
Sera were assayed for the presence of E-specific immunoglob-
ulins with both IgM and IgG antigen capture ELISA (MAC- and
GAC-ELISA). All VLP antigen concentrations were standardized
using the same antigen-capture described above in antigen
characterization section. Antigen concentrations were standard-
ized at an OD of 1.4, within the region of antigen excess near the
upper asymptote of the sigmoidal antigen dilution curve (antigen is
still the limiting factor here compared to the high concentration
polyclonal rabbit serum and MHIAF used to capture and detect
respectively). MAC- and GAC-ELISA were performed as
previously described with some modifications [29]. Briefly,
Immulon II HB flat-bottom 96-well plates were coated overnight
at 4uC with goat anti-human IgM or IgG (Kirkegaard & Perry
Laboratories, Gaithersburg, MD) and blocked with StartBlock.
DENV-2 infected patient sera and positive and negative control
sera were diluted 1:1000 in wash buffer, added to wells and
incubated at 37uC for 90 min. WT DENV-2 and negative control
antigens were diluted appropriately in wash buffer tested against
each serum sample in triplicate and incubated overnight at 4uC.
DENV-2 virus-infected MHIAF was diluted 1:2000 in 5% milk/
PBS and incubated for 1 h at 37uC. Horseradish-peroxidase
conjugated goat anti-mouse IgG was diluted in 5% milk/PBS,
50 ml, added to wells and incubated for 1 h at 37uC. Bound
conjugate was detected with TMB substrate and plates incubated
at room temperature for 8 min. The reaction was stopped with 2N
H2SO4 and ODs were measured at A450.
P/N ratios were calculated as previously described with test
validation utilizing internal positive and negative control sera on
each plate [66]. Positive values were determined as the average
OD for the patient serum sample reacted with WT DENV-2
antigen and negative values as the average OD of the normal
human control serum with WT DENV-2 antigen. The primary or
secondary DENV infection status of each specimen was deter-
mined by calculating the ratio of IgM/IgG OD each subtracted by
two times the corresponding negative value; ratios $1.2 are
indicative of primary infections and ratios ,1.2 of secondary
infections, Table 3 [67]).
Determination of E protein epitope-specific
immunoglobulin populations in DENV-2 infected human
sera
To quantify the epitope-specific humoral immune response
following DENV-2 infection we used the same MAC- and GAC-
ELISA format described above and serially diluted sera from
1610
3 to 1610
8. In addition to WT DENV-2 VLP antigen we
utilized a series of epitope-specific knock-out VLPs characterized
in this study (Table 2). Relative concentrations of WT and epitope-
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capture ELISA format described in the P/N analysis above. Sera
were diluted and tested with WT, five different epitope-specific
knock-outs, and negative antigen in duplicate at each serum
dilution. The five mutant DENV-2 VLP antigens used were an
EDII fusion peptide G106R-L107D cross-reactive knock-out
mutant (EDIIIFP), an EDIII K310E-E311R-P364R complex
cross-reactive knock-out mutant (EDIIICR), an EDII2EDIII
combination of these two mutants G106R-L107D-K310E-
E311R-P364R (EDIIFP2EDIIICR) and two single EDIII mutants
K305E and K388D (Table 2).
The resulting OD data were modeled as a nonlinear function of
the log10 dilution using a four-parameter logistic model. In a four
parameter logistic curve, the lower horizontal asymptote is not
constrained to zero. This model was chosen over the three
parameter model (which does constrain the lower asymptote to
zero) because although the sera can be diluted to the point where
there is no remaining immunoglobulin, the OD values are not
expected to reach zero. The model was fit with the S-plus (v8.0)
function nls (non-linear least squares) which uses least squares to
estimate the parameters. Sera, imunoglobulin type, and antigen
type were included as covariates. After fitting the model, endpoints
were computed by finding where the OD curves for each antigen
type crossed the OD curve for two times the negative control
values at each serum dilution. The asymptotic covariance matrix V
for the endpoints was computed using the multivariate delta
method [68]. Using V, general least squares was used to regress
endpoints on antigen type, IgM/IgG, primary/secondary infec-
tion status, and Taiwan/Puerto Rico geographic origin class.
Statistically significant main effects and two- and three-way
interactions were investigated further with multiple comparisons
using Scheffe’s method [69].
The model could not satisfactorily fit the data for Taiwan sera
#16 into a logistic curve, due to its very low positive OD signal,
since our highest concentration serum dilution (1:1000) only
captured the tail end of the actual curve of signal vs. antibody
concentration. Nevertheless, for both WT and all three EDIII
mutant antigens there was positive OD signal greater than two
times the negative value at the higher serum concentrations. For
this serum sample we therefore used the following linear
interpolation of the data to estimate the endpoint cut-offs,
endpoint=(mean OD of the antigen of interest at the last positive
serum dilution divided by two times the negative antigen OD at
the same serum dilution) multiplied by the last positive dilution.
Hence this is the percent remaining positive signal at the last
positive dilution times that last positive dilution.
Epitope-specific IgM and IgG percentages were calculated by
dividing the immunoglobulin end-point value obtained with a
specific knock-out antigen by that obtained with the WT antigen
on the same sera, subtracting this value from 1.0 and multiplying
by 100. The two EDIII single substitution antigens were included
to examine human immune responses to the protective EDIII
virus-specific neutralizing epitope were analyzed slightly different-
ly. K305E knocks out reactivity to neutralizing DENV-2 type-
specific MAbs (e.g. 3H5 in this study) and to complex cross-
reactive MAbs such as 1A1D-2; Table 2, [23,47]. K388 is not
incorporated into the DENV-2-specific epitope and knocks out
only complex cross-reactivity exemplified by MAb 1A1D-2
(Table 2, Fig. 2; [47]. Thus, the percent immunoglobulin
recognizing the DENV-2 specific EDIII neutralizing epitope was
calculated as 10061.0-[(K305 endpoint/WT endpoint)-(K388D
endpoint/WT endpoint)]. In a few cases the titer measured with a
mutant antigen was the same or greater than that with the WT
antigen. We interpreted these cases as undetectable levels of
antibody recognizing this epitope and the percent serum antibody
recognizing this epitope was conservatively set to 1% for further
analysis.
Virus Neutralization Assays
We utilized an immunostaining focus-reduction micro-neu-
tralization assay (FRmNT) to measure the neutralizing capability
of the human serum samples against all four DENV serotypes,
JEV and WNV. 2.47610
4 Vero cells in DMEM were added to
96 well black, clear flat bottom plates and incubated 16 hr
overnight at 37uCa n d5 %C O 2. Serum specimens were diluted
1:50 in BA-1 and heat inactivated at 56uC for 30 minutes,
diluted 2-fold to a final dilution of 1:1600 and 320 virus pfu was
added to each serum dilution. Plates were then incubated for
1h r a t 3 7 uC, 5% CO2. After incubation, serum and virus
suspensions were transferred back to Vero cell monolayer
containing plates. These Vero cell plates were incubated at
37uC, 5% CO2 for 45 minutes rocking every 5 minutes to allow
for virus infection. Barry’s Ye Lah overlay media containing 6%
sodium bicarbonate and 1% Carboxymethylcellulose sodium salt
(Fluka biochemical) was added and plates were incubated at
37uC, 5% CO2. Incubation times were as follows: WNV (NY-
99), JEV (SA-14-14-2): 24 hr; DENV-2 (16681) and DENV-4
(H241): 48 hr; DENV-1 (56BC94/95), DENV-3 (116RC1396):
70 hr. Following incubation plates were washed and fixed with
3:1 acetone, then decanted and plates were allowed to dry
overnight. Immunostaining was performed by adding virus-
specific MHIAFs diluted in PBS and incubated at 37uCf o r
30 min, washing and adding goat anti-mouse HRP diluted in 5%
milk/PBS and similarly incubated for 30 min. and washed.
Infected virus foci were visualized using Vector-VIP peroxidase
substrate kit SK-4600 as per manufacturers’ instructions. Foci
were counted using Zeiss KS300 microscope and Axiovision
software version 4.6. 90% FRmNT dilution titers were calculated
for each virus relative to that virus back-titration in BA-1. The
actual 90% neutralization titers were calculated using Graph pad
Prism version 4 (Graph Pad Software, San Diego, CA) sigmoidal
dose response (variable slope) formula. All reported values are
the average of two independent replicates.
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